Vial switch improves life-saving antiviral drug

22 Apr 2019

Legacy Pharmaceuticals uses SCHOTT Type I Plus vials to overcome a leaching issue.

Legacy Pharmaceuticals, a Swiss-based global contract manufacturer of sterile/aseptic pharmaceutical products in ampoules and vials, is collaborating with SCHOTT, a leading company in innovative glass production and technology, to solve a technical challenge. Legacy turned to SCHOTT Type I Plus vials to overcome a leaching issue for a life-saving antiviral drug product. This was successful, and Legacy and SCHOTT are now offering this solution to future customers with a need to provide better stability, particularly for highly sensitive formulations.

Vial switch improves life-saving antiviral drug

Protein adsorption and leaching from primary packaging are known to be root causes of reduced shelf life in many formulations. Ion leaching, especially for sodium, aluminium and other metal ions, forms uncoated type I glass and leads to pH shift and decreased stability or activity of biopharmaceuticals. The SCHOTT Type I Plus vials have an inside SiO2 coating with outstanding barrier properties.

“The barrier layer in the vials comes with multiple benefits: it prevents depletion of the glass container by the drug formulation and also acts as a diffusion barrier for all leachables of the glass matrix, supressing them to a level below their respective detection limit. The diffusion barrier is certified by a release test with a limit for sodium leaching (0.17 mg/l) less then 1/10 of the required sodium level for Type 1 containers (2.4 mg/l),” says Dr Bernhard Hladik, Senior Business Development Manager at SCHOTT.

This reduces the interaction between drug product and container surface, thereby providing a superior packaging solution for sensitive drug products.

“The number of injectable drugs coming to market continues to grow. However, many of the new formulations are highly sensitive. This imposes increasing demands on primary packaging - both vials and stoppers. Drawing on our longstanding expertise and knowledge of APIs and buffer systems, we proactively looked for new solutions to meet our customer’s demands. We have now identified, and validated the SCHOTT Type I Plus vials as a reliable option for our customers,“ commented Mike Danzi, CEO of Legacy Pharmaceuticals.

Read More

Related news

Improving gut health with human milk oligosaccharides

Improving gut health with human milk oligosaccharides

17 May 2019

2’-FL a very promising agent for digestive health across various age groups beyond infancy.

Read more 
Expert forecasts huge growth in Middle East manufacturing

Expert forecasts huge growth in Middle East manufacturing

16 May 2019

UAE consumers and insurance companies are willing to pay for highest quality drug products.

Read more 
Colorcon's breakthrough for direct compression

Colorcon's breakthrough for direct compression

15 May 2019

New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.

Read more 
Legacy plans for lyophilisation boom

Legacy plans for lyophilisation boom

14 May 2019

The increase in biologics is driving the growth in demand for lyophilization in vials.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Catalent achieves global ISO accreditation

Catalent achieves global ISO accreditation

12 May 2019

Company is one of the first CDMOs to receive award.

Read more 
Vibalogics increases capacity with a new 200-L line for virus manufacturing

Vibalogics increases capacity with a new 200-L line for virus manufacturing

9 May 2019

Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.

Read more 
New SIMCA 16 software for multivariate data analytics

New SIMCA 16 software for multivariate data analytics

8 May 2019

Makes model data easier to interpret for better process control.

Read more 
Recipharm launches its end-to-end inhalation offering

Recipharm launches its end-to-end inhalation offering

7 May 2019

Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.

Read more 
Accessible online courses designed to improve tablet compression tooling

Accessible online courses designed to improve tablet compression tooling

7 May 2019

I Holland launches online training for all levels of pharmaceutical and nutraceutical professionals.

Read more